Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Drug Offers Hope Against Tough-to-Treat Hypertension


Related Encyclopedia
 border=
Alzheimer's Disease
Aneurysms
Angina Pectoris
Angiogram
More...

Related Healthscout Videos
 border=
At-Home Stroke Rehab
Erectile Dysfunction Drugs Do More Than Arouse
New Life for Dying Hearts
Filling Cartilage Potholes
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Angioplasty
Animation: What is Hypertension?
Coronary Bypass Surgery
More...

Related Drug Information
 border=
Accupril
Actonel
Altace
Avapro
More...

Related News Articles
 border=
Men Seem More Susceptible to Memory Problems Than Women
Dementia Warning Signs Identified in Type 2 Diabetics: Study
Many Heart Patients Place False Hope in Angioplasty
Emergency Visits for Stomach Pain Rose Over Decade
More...


Page:  << Prev | 1 | 2

The study, done at 117 sites across the globe, enrolled 379 people with systolic blood pressure (the higher number in a reading) that remained at 140 or higher (130 for those with diabetes or chronic kidney disease). The recommended blood pressure reading is 120/80. All patients received 14 weeks of treatment with daily doses of 50, 100 or 300 milligrams of darusentan, or a placebo, an inactive substance.

On average, the participants' systolic blood pressure dropped 17 points with the 50-milligram dose of darusentan and 18 points with both the 100-milligram and the 300-milligram dose. A 9-point drop was recorded in the placebo group.

"That was a very meaningful reduction in blood pressure," said study lead author Dr. Michael A. Weber, professor of medicine in the cardiology division of State University of New York, Downstate College of Medicine. "Even if you subtract what happened in the placebo group, you still get about a 10-point drop, which is a clinically important finding. It translates into a meaningful reduction in the likelihood of strokes and other cardiovascular outcomes."

Text Continues Below



The major side effect was edema, excess fluid accumulation, which occurred in 27 percent of people taking the active drug and 14 percent of those taking placebo.

Because of edema, "to be really effective, darusentan probably should be used along with effective diuretic therapy," Weber said. Diuretics, which increase the flow of fluid from the body, are already widely used against high blood pressure.

If darusentan works as hoped, it will be especially useful for older people with resistant high blood pressure, Weber said. "They tend to be middle-aged or older, often with some impairment of kidney function," he said. "It is harder and harder to treat them and even more necessary to get their blood pressure treated, so new and more effective tools will be even more valuable."

More information

There's more on resistant high blood pressure at the American Heart Association.

Page:  << Prev | 1 | 2

Copyright © 2009 ScoutNews, LLC. All rights reserved.
Last updated 9/14/2009

Related Links
 border=
From Healthscout's partner site on heart disease, MyHeartCentral.com
Learn about heart disease symptoms.
Get more information on heart disease treatment for your health!
What can you do to prevent heart disease? Prevention details here.





SOURCES: Kirk Garratt, M.D., clinical director, interventional cardiovascular research, Lenox Hill Hospital, New York City; Nathan Kaiser, spokesman, Gilead Sciences, Foster City, Calif.; Michael A. Weber, M.D., professor of medicine, cardiology division, State University of New York, Downstate College of Medicine, Brooklyn, N.Y.; Sept. 13, 2009 The Lancet, online


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2010. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy